Navigation Links
ConvaTec Presents New Data on ConvaTec Moldable Technology™ and Vitala™ Continence Control Device in Ostomy Care
Date:6/7/2011

SKILLMAN, N.J., June 7, 2011 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today presented new data from multiple studies related to its advanced technologies in ostomy care including ConvaTec Moldable Technology™ and the Vitala™ Continence Control Device (CCD).  Results were presented at the Wound, Ostomy and Continence Nurses Society (WOCN) 43rd Annual Conference held June 4-8, 2011 in New Orleans, LA.

ConvaTec Moldable Technology™ Skin Barriers ConvaTec Moldable Technology™ Skin Barriers with Rebounding Memory Technology™ are the only skin barriers with a patented* tri-laminate construction that actively adjusts to the shape and contours of the stoma. ConvaTec Moldable Technology™ Skin Barriers are also backed by extensive clinical experience demonstrating their ability to prevent leaks and protect the peristomal skin.(1,2)  ConvaTec presented five abstracts on patient and heath care provider experiences with Moldable Technology™:  

  • A Survey of Quality of Life Measures in Patients Who Have Transitioned from Using a Non-Moldable Skin Barrier to a Moldable Skin Barrier (Abstract # 5452)

  • Skin Barrier Selection in an Outpatient Ostomy Clinic (Abstract # 5250)

  • The Perfect Fit: Moldable Technology in Home Care (Abstract # 5217)

  • The Road to Independence: Successful Use of Moldable Ostomy Skin Barriers to Improve Patient Outcomes (Abstract # 5137)

  • Use of a Moldable Skin Barrier with Adhesive Coupling to Manage Severely Denuded Peristomal Skin (Abstract # 5251)

  • Vitala™ Continence Control Device (CCD)Data was also presented data on the Vitala™ CCD, an innovative, non-invasive device that restores continence for up to 12 hours per day, allowing patients to manage their colostomy without having to wear a pouch or incorporate irrigatio
    '/>"/>

    SOURCE ConvaTec
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. New Data Supports ConvaTec Negative Pressure Wound Therapy
    2. ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing
    3. ConvaTec to Present at AdvaMed 2010: The MedTech Conference
    4. Bradford Barton Named President, ConvaTec U.S.
    5. ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering
    6. ConvaTec Announces New Appointments to Leadership Team
    7. ConvaTec Announces New Appointment to Leadership Team
    8. ConvaTec Healthcare Announces Plans to Refinance Secured Term Loans
    9. ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans
    10. Holy Family Medical Center Selects ConvaTec Negative Pressure for Wound Care
    11. ConvaTec Supported Studies to be Presented at the 24th Annual Symposium on Advanced Wound Care (SAWC) and Wound Healing Society (WHS)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
    (Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
    ... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... the extracellular matrix for the endocrinology, oncology, dermatology, ... of patient dosing for a Phase 1 clinical ... human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) ...
    ... (Nasdaq: ALXA ) today announced positive results ... loxapine). This Phase 3,clinical trial was conducted in ... 5 mg and 10 mg doses of AZ-004 met ... significant reduction in,agitation from baseline to the 2-hour post-dose ...
    Cached Medicine Technology:Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 2Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 2Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 3Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 4Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 5Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 6Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 7Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 8Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 9Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial 10
    (Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
    (Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
    (Date:4/17/2014)... Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently ... issue of Nature Reviews Microbiology , one ... McCullers, a world-renowned infectious disease specialist, and chair ... of Tennessee Health Science Center, analyzed the epidemiology ... and 1968 pandemics, as well as more recent ...
    (Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
    (Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
    Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
    ... called Katrina caused indelible havoc, visible by the huge numbers of ... victims’ lives.// The intangible consequences, not apparent on the face of ... mind of the survivors, torn by memories of the disaster, resulting ... ,The study has shown that nearly 15% ...
    ... Cancer Board has indicated that the Klein Government is all ... for early stage breast cancer.// The spokeswoman of the board, ... clinical trials in the United Kingdom before advising the $40,000-per-patient ... Herceptin is available to those patients who are in dire ...
    ... a little closer in understanding the evolution of the viruses ... more infectious to people. ,According to researchers ... strains from the common human influenza. This conclusion follows the ... flu viruses. This analysis will also aid scientists trace the ...
    ... According to trade sources, egg exports have been restarted ... dispatched its first egg shipment to Muscat.// ... February, all the countries around the world had stopped ... under control successfully by the several steps taken by ...
    ... Minister for Health Anbumani Ramadoss announced on Saturday that ... set up in the country and one of them ... by the Tamil Nadu State AIDS Control Society, Ramadoss ... ,Other routine activities would include blood extraction, ...
    ... prevent avian flu developed by a research institute in the ... paise per dose, amounting to less than a// cent, official ... Security Animal Disease Laboratory (HSADL), it is the first vaccine ... which has the technique for identifying the avian influenza virus ...
    Cached Medicine News:Health News:Understanding the Evolution of Viruses a little more Clearly 2Health News:‘Bird flu-free’ India resumes egg expor 2Health News:Bird Flu Vaccine Developed in India Could be Available for 35 Paise per Dose 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: